What the business is, and whether it's a good one at a fair price.
Manufactures active pharmaceutical ingredients (APIs) and industrial chemicals across two segments. The Pharmaceutical segment, which contributed 54.2% of FY26 segment revenue at ₹1,396.25 crore, makes Ibuprofen — where it is the largest global producer with 12,000 MTPA capacity — alongside a diversifying portfolio of non-Ibuprofen APIs such as Paracetamol, Metformin, Clopidogrel, Pantoprazole and Minoxidil, with the non-Ibuprofen share of pharma revenue rising from 18% in FY21 to 37% in FY26. The Chemical segment, 45.0% of segment revenue at ₹1,160.53 crore, produces Ethyl Acetate (1,20,000 MTPA), Acetic Anhydride (32,000 MTPA) and the newly commissioned Triacetin for backward integration, and was running at 98-100% capacity utilisation in Q4 FY26. Operations span 11 dedicated manufacturing units, with 14 USFDA DMFs and 21 EDQM CEPs in regulatory coverage, and products reach 80 countries. Q4 FY26 was the highest-ever quarter at ₹619 crore, lifting full-year revenue to ₹2,319.06 crore with EBITDA margin at 12.04%. Materials form the largest cost line at 64.8% of revenue, with employee cost at 10.7% and other opex at 13.6%.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from IOL CHEM AND PHARMA LTD's filed financials and exchange disclosures
IOL CHEM AND PHARMA LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol IOLCP.
Yes. Over the trailing twelve months IOL CHEM AND PHARMA LTD reported a net profit of ₹168 Cr on revenue of ₹2,524 Cr.
Yes. The dividend yield is 0.51% at the current price. It paid out 21% of its profit as dividend in FY26.
No. Debt stands at 0.07× equity, and it carries net debt of ₹67 Cr. That is lower than 55% of its 171 Pharmaceuticals peers.
On trailing P/E, IOL CHEM AND PHARMA LTD ranks 94 of 169 in Pharmaceuticals — cheaper than 45% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session IOL CHEM AND PHARMA LTD moves 1.79% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by IOL CHEM AND PHARMA LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
